WT1 Vaccine Doubles PFS in Phase II Trial
FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma.
CCL May – Mesothelioma WT1 Vaccine Doubles PFS in Phase II Trial
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Michele CarboneHaining YangMichele Carbone and Haining Yang, researchers at the University of Hawai’i Cancer Center, received a $2.5 million NCI grant to advance mesothelioma research by improving diagnosis and treatment for the disease.
Michigan State University’s School of Social Work has received $1,125,417 to co-lead a study aimed at improving psychosocial support for mesothelioma caregivers.
Researchers at Fox Chase Cancer Center and Temple Health were recently awarded a three year, $1.2 million grant to study sulforaphane, a promising cancer preventive agent derived from broccoli and other cruciferous vegetables, for the prevention of malignant mesothelioma.
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.
Andrea Wolf, director of the New York Mesothelioma Program at the Mount Sinai Health System, received the 2022 Irving J. Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization.
